Last reviewed · How we verify

Trifarotene cream — Competitive Intelligence Brief

Trifarotene cream (Trifarotene cream) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective retinoid X receptor (RXR) agonist. Area: Dermatology.

marketed Selective retinoid X receptor (RXR) agonist Retinoid X receptor (RXR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Trifarotene cream (Trifarotene cream) — Galderma R&D. Trifarotene is a selective retinoid X receptor (RXR) agonist that modulates gene expression to reduce inflammation and normalize skin cell differentiation in acne.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Trifarotene cream TARGET Trifarotene cream Galderma R&D marketed Selective retinoid X receptor (RXR) agonist Retinoid X receptor (RXR)
CD5789 (trifarotene) CD5789 (trifarotene) Galderma R&D phase 3 Selective retinoid X receptor (RXR) agonist Retinoid X receptor (RXR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective retinoid X receptor (RXR) agonist class)

  1. Galderma R&D · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trifarotene cream — Competitive Intelligence Brief. https://druglandscape.com/ci/trifarotene-cream. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: